Validation of the 99th percentile cutoff independent of assay imprecision (CV) for cardiac troponin monitoring for ruling out myocardial infarction.

By definition, the probability that a single measured cardiac troponin result exceeds the estimated 99th percentile is equal to 0.01 (1%) for a person randomly selected from the general (reference) population. This is irrespective of the imprecision profile of the analytical method as well as the lack of standardization of cardiac troponin assays (1)(2)(3)(4)(5)(6)(7). However, the probability that a measured result exceeds the 99th percentile limit for a specific person from the reference population will vary depending on that person’s true concentration and on the imprecision profile of the specific analytical method. Furthermore, the overall probability that at least one of multiple measured values (the second or third measured cardiac troponin concentration in a timed series of cardiac troponin orders) exceeds the 99th percentile also will vary depending on the imprecision of the analytical method. To investigate the influence of assay imprecision on the likelihood of misclassifying healthy individuals or patients without myocardial injury, we simulated the distribution of cardiac troponin I (cTnI) results in a general population and added random analytical error reflecting different assay imprecision profiles. One imprecision profile assumes a CV of 37.5% at a cTnI of 0.05 μg/L, decreasing to a CV of 25% at a cTnI of 0.07 μg/L, …

[1]  A. Wu,et al.  Evaluation of imprecision for cardiac troponin assays at low-range concentrations. , 2004, Clinical chemistry.

[2]  Fred S Apple,et al.  European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. , 2002, American heart journal.

[3]  Mauro Panteghini,et al.  Performance of today's cardiac troponin assays and tomorrow's. , 2002, Clinical chemistry.

[4]  L. Wallentin,et al.  Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy). , 2002, The American journal of cardiology.

[5]  E. Braunwald,et al.  Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.

[6]  A. Wu,et al.  Quality Specifications for Cardiac Troponin Assays , 2001, Clinical chemistry and laboratory medicine.

[7]  A. Wu,et al.  Myocardial infarction redefined: role of cardiac troponin testing. , 2001, Clinical chemistry.

[8]  A. Jaffe,et al.  Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. , 2000, American heart journal.

[9]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[10]  A. Jaffe,et al.  It's time for a change to a troponin standard. , 2000, Circulation.

[11]  E. Antman,et al.  Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. , 2000, Clinical chemistry.